These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17482939)

  • 21. Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapy.
    Ihrig A; Keller M; Hartmann M; Debus J; Pfitzenmaier J; Hadaschik B; Hohenfellner M; Herzog W; Huber J
    BJU Int; 2011 Oct; 108(8):1274-8. PubMed ID: 21410634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An approach to measuring the quality of breast cancer decisions.
    Sepucha K; Ozanne E; Silvia K; Partridge A; Mulley AG
    Patient Educ Couns; 2007 Feb; 65(2):261-9. PubMed ID: 17023138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
    Guzzo TJ; Levin BM; Lee R; Guo M; Chen Z; Whittington R; Tomaszewski J; Malkowicz SB
    Urology; 2008 Apr; 71(4):723-7. PubMed ID: 18387401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer.
    Davison BJ; Oliffe JL; Pickles T; Mroz L
    Oncol Nurs Forum; 2009 Jan; 36(1):89-96. PubMed ID: 19136342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
    Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
    Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Information needs and prostate cancer: the development of a systematic means of identification.
    Dale J; Jatsch W; Hughes N; Pearce A; Meystre C
    BJU Int; 2004 Jul; 94(1):63-9. PubMed ID: 15217433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical judgment analysis of the parameters used by consultant urologists in the management of prostate cancer.
    Clarke MG; Wilson JR; Kennedy KP; MacDonagh RP
    J Urol; 2007 Jul; 178(1):98-102. PubMed ID: 17499280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The surgical learning curve for prostate cancer control after radical prostatectomy.
    Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
    J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoting prostate-specific antigen informed decision-making. Evaluating two community-level interventions.
    Driscoll DL; Rupert DJ; Golin CE; McCormack LA; Sheridan SL; Welch BM; Poehlman JA
    Am J Prev Med; 2008 Aug; 35(2):87-94. PubMed ID: 18617077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health information styles among participants in a prostate cancer screening informed decision-making intervention.
    Williams-Piehota PA; McCormack LA; Treiman K; Bann CM
    Health Educ Res; 2008 Jun; 23(3):440-53. PubMed ID: 18385197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.